Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.61 |
| ▸ | TP53 | P04637 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.48 |
| ▸ | HPGD | P15428 | 7/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615690 | 1.00 | KDM4E (0.61) | KDM4EMAPTTP53SMN1; SMN2CYP3A4 | |
| SCHEMBL27188738 | 0.81 | KDM4E (0.53) | KDM4EMAPTTP53SMN1; SMN2CYP3A4 | |
| SCHEMBL4814056 | 0.80 | RAB9A (0.46) | KDM4EMAPTTP53SMN1; SMN2CYP3A4 | |
| SCHEMBL9227523 | 0.79 | MAPT (0.45) | KDM4EMAPTTP53SMN1; SMN2CYP3A4 | |
| SCHEMBL4815082 | 0.79 | MAPT (0.48) | KDM4EMAPTTP53SMN1; SMN2CYP3A4 | |
| SCHEMBL11533852 | 0.78 | KDM4E (0.49) | KDM4EMAPTTP53SMN1; SMN2CYP3A4 | |
| SCHEMBL5264214 | 0.76 | MAPT (1.00) | KDM4EMAPTTP53SMN1; SMN2CYP3A4 | |
| SCHEMBL8209185 | 0.76 | KDM4E (0.74) | KDM4EMAPTTP53SMN1; SMN2CYP3A4 | |
| SCHEMBL30617062 | 0.76 | MAPT (1.00) | KDM4EMAPTTP53SMN1; SMN2CYP3A4 | |
| SCHEMBL29479235 | 0.76 | KDM4E (0.74) | KDM4EMAPTTP53SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230114408-A1 | METHODS OF MODULATING T-CELL ACTIVATION USING ESTROGEN RECEPTOR BETA (ERB) AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-13 | — | — | US | disclosed |
| WO-2021183760-A1 | METHODS OF MODULATING T-CELL ACTIVATION USING ESTROGEN RECEPTOR BETA (ERΒ) AGONISTS | OHIO STATE INNOVATION FOUNDATION (US) | 2021-09-16 | — | — | WO | disclosed |
| WO-2020160225-A1 | ESTROGEN RECEPTOR BETA (ERβ) AGONISTS FOR THE TREATMENT OF FIBROTIC CONDITIONS | OHIO STATE INNOVATION FOUNDATION (US) | 2020-08-06 | — | — | WO | disclosed |
| EP-2125825-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABELMAN MATTHEW | 2008-11-27 | — | — | US | disclosed |
| US-7432276-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7423045-B2 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2008079139-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-7354927-B2 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354927-B2 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070191379-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1789420-A2 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth, A Corporation of the State of Delaware (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1789420-A2 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth, A Corporation of the State of Delaware (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20070010544-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-01-11 | — | — | US | disclosed |
| WO-2006029146-A3 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | WYETH CORP (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006029146-A2 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006029146-A2 | 6H-[1]BENZOPYRANO[4,3-b]QUINOLINES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060052410-A1 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2006-03-09 | — | — | US | disclosed |
| US-20060052410-A1 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2006-03-09 | — | — | US | disclosed |
| US-20060052410-A1 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | WYETH (US) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191379-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | KDM4E 4502/4885MAPT 4361/4885TP53 4391/4885 |
| US-20080293757-A1 | ABCA1 ELEVATING COMPOUNDS | ABCD3, ABCB4, CETP | KDM4E 4502/4885MAPT 4361/4885TP53 4391/4885 |
| US-20070010544-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | KDM4E 4502/4885MAPT 4361/4885TP53 4391/4885 |
| US-20230114408-A1 | METHODS OF MODULATING T-CELL ACTIVATION USING ESTROGEN RECEPTOR BETA (ERB) AGONISTS | ESRRG, ESR2, ESRRB | KDM4E 3512/4885MAPT 4646/4885TP53 4054/4885 |
| US-20060052410-A1 | 6H-[1]benzopyrano[4,3-b]quinolines and their use as estrogenic agents | CYP19A1, ESR1, ESR2 | KDM4E 546/4885MAPT 3973/4885TP53 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.